553 related articles for article (PubMed ID: 31203578)
21. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
Le Quellec S
Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
[TBL] [Abstract][Full Text] [Related]
22. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
23. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
24. Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Kaneda M; Kawasaki R; Matsumoto N; Abe H; Tashiro Y; Inokuchi Y; Yasuno H; Sasaki-Noguchi M; Soeda T; Yoshimura Y; Oka T
J Thromb Haemost; 2021 Dec; 19(12):2938-2946. PubMed ID: 34418287
[TBL] [Abstract][Full Text] [Related]
25. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
[TBL] [Abstract][Full Text] [Related]
26. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
Nougier C; Jeanpierre E; Ternisien C; Proulle V; Hezard N; Pouplard C; Lasne D;
Eur J Haematol; 2020 Dec; 105(6):675-681. PubMed ID: 32668090
[TBL] [Abstract][Full Text] [Related]
27. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
[TBL] [Abstract][Full Text] [Related]
28. Hemophilia A: Emicizumab monitoring and impact on coagulation testing.
Nardi MA
Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648
[TBL] [Abstract][Full Text] [Related]
29. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
Nogami K
Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
[TBL] [Abstract][Full Text] [Related]
30. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
31. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
[TBL] [Abstract][Full Text] [Related]
32. Emicizumab Augments Thrombus Formation in Whole Blood from Patients with Hemophilia A under High Shear Flow Conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Haemost; 2021 Mar; 121(3):279-286. PubMed ID: 32906155
[TBL] [Abstract][Full Text] [Related]
33. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
34. Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy.
Hatayama Y; Motokura T; Hosoda Y; Suzuki S; Namba H; Kato K; Kojima N; Horie T; Iwamoto T; Yamashita N; Ichikawa H; Fukuda T
Clin Appl Thromb Hemost; 2022; 28():10760296221082992. PubMed ID: 35225012
[TBL] [Abstract][Full Text] [Related]
35. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors.
Carcao M; Mancuso ME; Young G; Jiménez-Yuste V
Expert Rev Hematol; 2021 Feb; 14(2):143-148. PubMed ID: 33499681
[No Abstract] [Full Text] [Related]
36. Emicizumab-kxwh: First Global Approval.
Scott LJ; Kim ES
Drugs; 2018 Feb; 78(2):269-274. PubMed ID: 29357074
[TBL] [Abstract][Full Text] [Related]
37. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
38. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
39. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
40. Emicizumab for hemophilia A without inhibitors.
Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]